Aortic Dissection | NYU Langone Health
NYU Langone cardiologists, cardiothoracic surgeons, and vascular surgeons are highly trained in diagnosing and treating aortic dissections.
Aortic Valve Disease | NYU Langone Health
NYU Langone cardiologists, cardiothoracic surgeons, and interventional cardiologists are highly trained in managing aortic valve disease.
Aortoiliac Occlusive Disease | NYU Langone Health
NYU Langone vascular specialists manage aortoiliac occlusive disease, which limits blood flow to the pelvis and legs.
APEC1621SC: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
The Pediatric MATCH (Molecular Analysis for Therapy Choice) study, (referred to as Pediatric MATCH in the remainder of this document), will match targeted agents with specific molecular changes identified using genomic sequencing technologies in refractory/recurrent tumors from children and adolescents with cancer. Pediatric MATCH will build upon experience from the adult NCI MATCH clinical trial. PediatricMATCH will be a national trial under a single IND and will be led by NCI and the Children’s Oncology Group (COG), a member of the NCI National Clinical Trial Network (NCTN). Pediatric MATCH will employ an analytically validated next-generation sequencing targeted assay of more than 4,000 different mutations (SNVs, indels, copy number alterations, and gene fusions) across more than 140 genes. This assay will be coupled to a computer algorithm that uses pre-existing definitions and prioritization of target-agent pairs to assign patients by actionable mutation results to a targeted treatment.The primary endpoint for Pediatric MATCH will be objective response rate. The study will use a trial design with the flexibility to open and close arms. The study drugs included in this trial will include agents that have at least an adult recommended phase 2 dose and that have shown some activity against tumors with a particular genetic alteration(s). Patients with recurrent or refractory tumors enrolled on study willhave a tumor sample available for molecular characterization, and those with molecular variants addressed by treatments included in the trial will be offered treatment on Pediatric MATCH.
APOL1 Long-term Kidney Transplantation Outcomes Network
The National Institutes of Health (NIH)-sponsored collaborative APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is charged with prospectively assessing the effects of renal-risk variants (RRVs) in the apolipoprotein L1 gene (APOL1) on outcomes for kidneys from donors with recent African ancestry and the recipients of their kidneys, after deceased- and living-donor renal transplantation. For the purposes of APOLLO, recent African ancestry is defined as individuals with similar genetic make-up to those currently residing in Africa. APOLLO will also study the impact of APOL1 RRVs on the health of living kidney donors with recent African ancestry.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Apps | NYU Langone Health
NYU Langone Health has launched several mobile apps to improve access to patient care and to conduct research studies.
Arrange a Speaker from Perlmutter Cancer Center | NYU Langone Health
Experts from NYU Langone’s Perlmutter Cancer Center deliver educational programs to outside organizations through our speakers bureau.
Arrhythmias in Children | NYU Langone Health
Heart specialists at Hassenfeld Children’s Hospital at NYU Langone provide expert care for babies and children with arrhythmias.
Art Program | NYU Langone Health
The NYU Langone Art Program and Collection integrates artwork of the highest quality into the healing environments of our facilities.